StockNews.com Begins Coverage on NeuroMetrix (NASDAQ:NURO)

Research analysts at StockNews.com began coverage on shares of NeuroMetrix (NASDAQ:NURO) in a research report issued to clients and investors on Tuesday. The firm set a “sell” rating on the medical device company’s stock.

NeuroMetrix Stock Performance

Shares of NASDAQ:NURO opened at $4.36 on Tuesday. The company’s 50-day moving average is $4.40 and its 200 day moving average is $4.20. The company has a market capitalization of $8.98 million, a P/E ratio of -0.95 and a beta of 1.82. NeuroMetrix has a fifty-two week low of $2.66 and a fifty-two week high of $4.73.

Hedge Funds Weigh In On NeuroMetrix

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. GTS Securities LLC purchased a new position in shares of NeuroMetrix in the 4th quarter worth about $90,000. Deltec Asset Management LLC purchased a new position in shares of NeuroMetrix in the 1st quarter worth about $81,000. Finally, Renaissance Technologies LLC bought a new stake in NeuroMetrix in the 4th quarter valued at about $46,000. 19.40% of the stock is owned by hedge funds and other institutional investors.

NeuroMetrix Company Profile

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.